Advanced primary peritoneal carcinoma: Clinicopathological and prognostic factor analyses

Journal of Zhejiang University: Science B

Volumn 9, Issue 6, 2008, Pages 435-440

  Zhang, Chao ^a   Li, Xiao Ping ^a   Cui, Heng ^a   Shen, Dan Hua ^a   Wei, Li Hui ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Chemotherapy; Cytoreductive surgery; Immunohistochemistry; Primary peritoneal carcinoma (PPC); Prognosis

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETOPOSIDE; KI 67 ANTIGEN; PACLITAXEL; PIRARUBICIN; PROTEIN P53;

ADULT; ADVANCED CANCER; AGE; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CYTOREDUCTIVE SURGERY; FACTORIAL ANALYSIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MENOPAUSE; MIXED MULLERIAN TUMOR; MONOTHERAPY; OVERALL SURVIVAL; PERITONEUM CANCER; PRIMARY PERITONEUM CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR VOLUME;

ADULT; AGED; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHINA; COMBINED MODALITY THERAPY; CYSTADENOCARCINOMA, PAPILLARY; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; MIXED TUMOR, MULLERIAN; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROGNOSIS; RECEPTOR, ERBB-2; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 44849105142     PISSN: 16731581     EISSN: 18621783     Source Type: Journal    
DOI: 10.1631/jzus.B0820051     Document Type: Article

References (21)

1. Altaras, M.M., Aviram, R., Cohen, I., Cordoba, M., Weiss, E., Beyth, Y., 1990. Primary peritoneal papillary serous adenocarcinoma: Clinical and management aspects. Gynecol. Oncol., 40 (3):230-236. [doi:10.1016/ 0090-8258(90)90283-Q]
2. Ben-Baruch, G., Sivan, E., Moran, O., Rizel, S., Menczer, J., Seidman, D.S., 1996. Primary peritoneal serous papillary carcinoma: A study of 25 cases and comparison with stage III-IV ovarian papillary serous carcinoma. Gynecol. Oncol., 60 (3):393-396. [doi:10.1006/gyno.1996.0060]
3. Bloss, J.D., Liao, S.Y., Buller, R.E., Manetta, A., Berman, M.L., McMeekin, S., Bloss, L.P., DiSaia, P.J., 1993. Extraovarian peritoneal serous papillary carcinoma: A case-control retrospective comparison to papillary adenocarcinoma of the ovary. Gynecol. Oncol., 50 (3):347-351. [doi:10.1006/gyno.1993.1223]
4. Bloss, J.D., Brady, M.F., Liao, S.Y., Rocereto, T., Partridge, E.E., Clarke-Pearson, D.L., Gynecologic Oncology Group Study, 2003. Extraovarian peritoneal serous papillary carcinoma: A phase II trial of cisplatin and cyclophosphamide with comparison to a cohort with paillary serous ovarian carcinoma. Gynecol. Oncol., 89 (1):148-154. [doi:10.1016/ S0090-8258(03)00068-4]
5. Chu, C.S., Menzin, A.W., Leonard, D.G., Rubin, S.C., Wheeler, J.E., 1999. Primary peritoneal carcinoma: A review of the literature. Obstet. Gynecol. Surv., 54 (5):323-335. [doi:10.1097/00006254-199905000-00023]
6. Dubernard, G., Morice, P., Rev, A., Camatte, S., Fourchotte, V., Thoury, A., Pomel, C., Pautier, P., Lhommé, C., Duvillard, P., 2004. Prognosis of stage III or IV primary peritoneal serous papillary carcinoma. Eur. J. Surg. Oncol., 30 (9):976-981. [doi:10.1016/ j.ejso.2004.08.005]
7. Eltabbakh, G.H., Werness, B.A., Piver, S., Blumenson, L.E., 1998a. Prognostic factors in extraovarian primary peritoneal carcinoma. Gynecol. Oncol., 71 (2):230-239. [doi:10.1006/gyno.1998.5090]
8. Eltabbakh, G.H., Piver, M.S., Natarajan, N., Mettlin, C.J., 1998b. Epidemiologic differences between women with extraovarian primary peritoneal carcinoma and women with epithelial ovarian cancer. Obstet. Gynecol., 91 (2):254-259. [doi:10.1016/S0029-7844(97)00650-9]
9. Fromm, G.L., Gershenson, D.M., Silva, E.G., 1990. Papillary serous carcinoma of the peritoneum. Obstet. Gynecol., 75 (1):89-95.
10. Garamvoelgyi, E., Guillou, L., Gebhard, S., Salmeron, M., Seematter, R.J., Hadji, M.H., 1994. Primary malignant mixed mullerian tumor (metaplastic carcinoma) of the female peritoneum: A clinical, pathologic and immunohistochemical study of three cases and a review of the literature. Cancer, 74 (3):854-863. [doi:10.1002/ 1097-0142(19940801)74:3∼854::AID-CNCR2820740311∼3.0.CO;2-R]
11. Gotlieb, W.H., Goldberg, I., Weisz, B., Davidson, B., Novikov, I., Kopolovic, J., Ben-Baruch, G., 2001. Topoisomerase II immunostaining as a prognostic marker for survival in ovarian cancer. Gynecol. Oncol., 82 (1):99-104. [doi:10.1006/gyno.2001.6208]
12. Halperin, R., Zehavi, S., Hadas, E., Habler, L., Bukovsky, I., Schneider, D., 2001. Immunohistochemical comparison of primary peritoneal and primary ovarian serous papillary carcinoma. Int. J. Gynecol. Pathol., 209 (4):341-345. [doi:10.1097/00004347-200110000-00005]
13. Killackey, M.A., Davis, A.R., 1993. Papillary serous carcinoma of the peritoneal surface: Matched-case comparison with papillary serous ovarian carcinoma. Gynecol. Oncol., 51 (2):171-174. [doi:10.1006/ gyno.1993.1267]
14. Kowalski, L.D., Kanbour, A.I., Price, F.V., Finkelstein, S.D., Christopherson, W.A., Seski, J.C., Naus, G.J., Burnham, J.A., Kanbour-Shakir, A., Edwards, R.P., 1997. A casematched molecular comparison of extraovarian versus primary ovarian adenocarcinoma. Cancer, 79 (8):1587-1594. [doi:10.1002/ (SICI)1097-0142(19970415)79:8<1587::AID-CNCR22>3.0.CO;2-T]
15. Look, M., Chang, D., Sugarbaker, P.H., 2004. Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Int. J. Gynecol. Cancer, 14 (1):35-41. [doi:10.1111/j.1048-891x.2004.14008.x]
16. Menzin, A.W., Aikins, J.K., Wheeler, J.E., Rubin, S.C., 1996. Surgically documented responses to paclitaxel and cisplatin patients with primary peritoneal carcinoma. Gynecol. Oncol., 62 (1):55-58. [doi:10.1006/ gyno.1996.0189]
17. Mills, S.E., Andersen, W.A., Fechner, R.E., Austin, M.B., 1988. Serous surface papillary carcinoma: A clinicopathologic study of 10 cases and comparison with stage III-IV ovarian serous carcinoma. Am. J. Surg. Pathol., 12 (11):827-834.
18. Muto, M.G., Welch, W.R., Mok, S.C., Bandera, C.A., Fishbauqh, P.M., Tsao, S.W., Lau, C.C., Goodman, H.M., Knapp, R.C., Berkowitz, R.S., 1995. Evidence for a multifocal origin of papillary serous carcinoma of the peritoneum. Cancer Res., 55 (3):490-492.
19. Piver, M.S., Eltabbakh, G.H., Hempling, R.E., Recio, F.O., Blumenson, L.E., 1997. Two sequential studies for primary peritoneal carcinoma: induction with weekly cisplatin followed by either cisplatin-doxorubicin-cyclophosphamide or paclitaxel-cisplatin. Gynecol. Oncol., 67 (2):141-146. [doi:10.1006/gyno.1997.4843]
20. Shen, D.H., Khoo, U.S., Xue, W.C., Ngan, H.Y., Wang, J.L., Liu, V.W., Chan, Y.K., Cheung, A.N., 2001. Primary peritoneal malignant mixed Mullerian tumors. A clinicopathologic, immunohistochemical and genetic study. Cancer, 91 (5):1052-1060. [doi:10.1002/ 1097-0142(20010301)91:5<1052::AID-CNCR1097>3.3.CO;2-1]
21. Swerdlow, M., 1959. Mesothelioma of the pelvic peritoneum resembling papillary cystadeno-carcinoma of the ovary. Case Report. Am. J. Obstet. Gynecol., 77 (1):197-200.